Wall Street Analyst Raises Eli Lilly Target to $1,400 Following Pipeline Gains
New York, Wednesday, 16 September 2026.
Berenberg upgraded Eli Lilly to a Buy rating, raising its price target to $1,400 after admitting it previously underestimated the pharmaceutical giant’s expanding external pipeline.
Wall Street Analyst Raises Eli Lilly Target to $1,400 Following Pipeline Gains
Berenberg upgraded Eli Lilly to a Buy rating, raising its price target to $1,400 after admitting it previously underestimated the pharmaceutical giant’s expanding external pipeline [1]. This adjustment reflects heightened investor attention on major Wall Street equities under intense institutional scrutiny during mid-September 2026 trading sessions [1]. Investors and corporate executives are closely observing Eli Lilly’s market positioning amid ongoing demand for metabolic treatments, while defense titan Lockheed Martin Corporation provides key indicators for sector allocation in the autumn quarter [1][2].
Analyst Confidence and Price Target Adjustment
On 2026-09-15, Berenberg upgraded Eli Lilly (LLY) from Hold to Buy and increased its price target from $1,220 to $1,400 [1]. This adjustment represents a potential upside calculated as 14.754 percent over the previous target [1]. The analyst firm noted underestimated external pipeline moves as a primary driver for the revised outlook [1]. Eli Lilly and Company market performance on 2026-09-15 showed a price of US$1,136.11, with a change of -0.19% and volume of 1,887,653 shares [1]. Prior to this, on 2026-09-14, the stock price was US$1,138.28, reflecting a change of +2.02% [1].
Market Performance and Sector Context
Broader market data confirms trading activity on 09/15/2026, with the DJIA close recorded at 52093.11 [3]. While Eli Lilly draws attention for metabolic treatments, Lockheed Martin Corporation specializes in the design, manufacturing and marketing of aeronautic, submarine, and aerospace systems [2]. Net sales for Lockheed Martin break down by activity, with sale of aeronautic systems accounting for 40.3% of the total [2]. Geographic net sales distribution for Eli Lilly shows the United States contributing 66.7% of net sales, whereas Lockheed Martin derives 71.6% of net sales from the United States [1][2]. Endocrinology remains the dominant therapeutic field for Eli Lilly, representing 74% of net sales distribution [1].